Thursday, October 28, 2021
Home Generic Drugs

Generic Drugs

The Optometry Times says generic topical medications for glaucoma are not always equal to their brand-name counterparts. It is important to check with your doctor before switching to any generic drugs for glaucoma because there are a few potential risks associated with quality control.
Dr. Reddy’s Laboratories, an Indian-based pharma company, has announced that it has received approval from the FDA to market generic lenalidomide (Revlimid) for the treatment of various cancers. The company said it would sell the drug in the US market from March 2022.
Dr. Qing Yang and husband Kevin Parker have recently written an article in The State Journal-Register, explaining the pros and cons of generic drugs. They say quality control of generic drugs is a primary concern, as most of the generic drugs come from India and China.
Generic drugs for beta blockers available in the United States include acebutolol, atenolol, bisoprolol, metoprolol, nadolol, and timolol. These drugs are advised for the treatment of high blood pressure, heart failure, and heart rhythm disorders. They also help prevent heart attacks.
New research, published in JAMA Internal Medicine, has found that approved generic drugs for insulin and antiviral agents for treating hepatitis C may lower drug prices for patients but they are unlikely to provide savings to Medicare D Part beneficiaries.
The Food and Drug Administration (FDA) has approved generic Doxorubicin-HCI Liposomal Injection for the treatment of ovarian cancer, multiple myeloma, and Kaposi’s Sarcoma. Ayana, an Israeli-based pharma company, develops this generic cancer drug.
Generic drug company Teligent, New Jersey, has filed for “Chapter 11” protection in U.S. bankruptcy court in Wilmington, Delaware, planning to sell itself. The company has cited regulatory and legal setbacks after receiving a warning letter from the FDA related to its manufacturing processes.

MOST POPULAR

WE'RE SOCIAL

63FansLike
108FollowersFollow
526FollowersFollow
0SubscribersSubscribe